NEWS
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
• Phase 2 trial is an adaptive designed randomized study comparing NGC-Cap to monotherapy capecitabine
• Results from this Phase 2 trial will evaluate NGC-Cap's safety-efficacy profile and help to define the optimal dosage regimen in patients with metastatic breast cancer
• Results from this Phase 2 trial will evaluate NGC-Cap's safety-efficacy profile and help to define the optimal dosage regimen in patients with metastatic breast cancer
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2918Followers
108Following
30KVisitors
Follow
Jaguar8 OP 151764120 : Thanks for that. It got missed today